Educational Resources

  • Explore emerging real-world evidence in front-line BPDCN

    Posted on 09/17/202


    This new publication explores real-world safety and efficacy in patients treated with a CD123 targeted therapy in newly diagnosed blastic plasmacytoid dendritic cell neoplasms.

    View Resource



  • A Children’s Book for Families with MBC

    Posted on 09/11/2025


    Living with metastatic breast cancer and looking for more whole-family support? Get a discussion guide for The Adventure Jar, printouts to make own of your own, and more at Support for Families.

    Learn More



  • OPDIVO Qvantig™ permanent J-code available as of July 1, 2025

    Posted on 08/20/2025

     

    CMS has granted a unique J-code, J9289, for the use of OPDIVO Qvantig™ across all outpatient settings. J9289 is effective for dates of service on or after July 1, 2025. Bristol Myers Squibb would appreciate your partnership in updating systems and locations involved with the HCPCS and NDC information for J9289..

    Learn More



  • The Different Colors of Skin Cancer Brochure

    Posted on 07/22/2025

     

    This brochure from Regeneron provides helpful information on advanced CSCC and advanced BCC in patients of color.

    View Resource



  • Precision Medicine at J&J is working to advance cancer care across multiple diseases with biomarker-informed treatments in oncology.

    Posted on 07/01/2025

     

    Scan to visit our website and learn more: Here


    Data rates may apply.



  • New XOFIGO® (radium-223 dichloride) Data in Metastatic Castration-Resistant Prostate Cancer from Phase III PEACE III Trial Published in Annals of Oncology

    Posted on 06/09/2025

     

    Annals of Oncology published full results from the pivotal investigational Phase III PEACE III trial, evaluating XOFIGO® (radium-223 dichloride) in combination with enzalutamide, an AR pathway inhibitor (ARPI), versus enzalutamide alone in the first-line treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

    View Resource



  • Cancer of unknown primary (CUP): Implementation of a robust pathway

    Posted on 05/27/2025

     

    There is a need to improve upon the diagnostic strategies for cancer of unknown primary ​(CUP) tumors​. And reducing delays in diagnosis and identifying patients at earlier stages may potentially ​improve patient outcomes. These guides aim to highlight key considerations to take into account when establishing a robust CUP pathway in academic and community centers across the US​.

    View First Resource View Second Resource



  • Jazz Pharmaceuticals Study for Adults Suffering from HER2-positive Biliary Tract Cancer

    Posted on 05/14/2025

     

    Jazz Pharmaceuticals is sponsoring a clinical study evaluating the safety and efficacy of an investigational medicine called zanidatamab for the treatment of advanced HER2-positive biliary tract cancer. Visit Biliary Tract Cancer Study - Inform Herizon BTC-302 Study - Jazz Pharmaceuticals or click the resource below to learn more.

    View Resource



  • This Is Living With Cancer™

    Posted on 04/24/2025

    This Is Living With Cancer™ is a free online resource developed by Pfizer Oncology for all people living with cancer, regardless of age, income, race, location, cancer type, or stage of disease. This comprehensive program is available to anyone in the United States, whether they're on a Pfizer treatment or not, with a growing focus on those facing challenges accessing care.

    Direct your patients to ThisIsLivingWithCancer.com to learn more.

    View Resource



  • Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

    Published on: February 17, 2025

    Watch Dr. David Sallman, a leading MDS specialist at the Moffitt Cancer Center, talk about the importance of investigating unexplained anemia.

    View Resource Here





1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
msco-minnesota.com
Email Us